Posted on 7/9/19
Johnson & Johnson: 8-9% Annual Total Return Potential Makes This Dividend Aristocrat A Hold
SummaryHaving raised its dividend every year since the Kennedy administration, Johnson & Johnson is on the prestigious Dividend Kings list.Despite the risks of being a scapegoat . . .
Posted on 7/9/19
Why Bristol-Myers Squibb Stock Plunged in the First Half of 2019
What happenedPrescription drug giant Bristol-Myers Squibb (NYSE:BMY) lost an eye-catching 12.8% of its value during the first six months of 2019, according to data from S&P . . .
Posted on 7/9/19
Phreesia Launches IPO of Common Stock
Phreesia, Inc., a leading patient intake management platform, today announced that it has commenced an initial public offering of its common stock. Phreesia is offering 7,812,500 . . .
Posted on 7/8/19
Kaleidoscope Labs Lands $4M Seed Round
Rising functional wellness and CBD brand, Kaleidoscope Labs, which launched on July 1, has raised a $4M seed round support their expansion efforts.
Posted on 7/8/19
Better Buy: Pfizer vs. Johnson & Johnson
If you've taken a look at Pfizer (NYSE:PFE) or Johnson & Johnson (NYSE:JNJ) recently, you've probably noticed both companies have been reporting stagnant revenue growth that . . .
Posted on 7/8/19
Is bluebird bio a Buy?
Gene therapy stocks attracted frenzied attention from investors in 2017 and early 2018, and with good reason. New technologies to manipulate the very software of life . . .
Posted on 7/8/19
Here's Why Axsome Therapeutics Stock Rocketed 813% in the First Half of 2019
What happenedShares of Axsome Therapeutics (NASDAQ:AXSM), an overlooked biopharmaceutical company that began 2019 with an $85 million market cap, finished the first half of the year . . .
Posted on 7/8/19
Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing
CRANBURY, N.J., July 02, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (NASDAQ:FOLD) has entered into a strategic manufacturing agreement with Paragon Gene Therapy, a unit of . . .
Posted on 7/3/19
Bristol-Myers: Otezla Divestiture Highlights Compelling Opportunity
Summary Bristol-Myers reported that it will divest Celgene’s psoriasis product Otezla to ease FTC’s anti-trust concerns. The divestiture will result in BMY pushing the BMY/CELG deal . . .
Posted on 7/3/19
District Judge Issues Final Judgment in Favor of RMS Medical Products
CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced that on June 28, 2019 the United States District Judge for the Eastern . . .
Posted on 7/3/19
Arbutus Sells Part of Its ONPATTRO (patisiran) Royalty Interest To OMERS
Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the sale of part of its royalty interest
Posted on 7/2/19
Cybrexa Therapeutics Receives SBIR Grant to Support Development of Lead Candidate CBX-11 in Combination with Chemotherapy Agents
NEW HAVEN, Conn., July 02, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting . . .
Posted on 7/1/19
Momentous Shifts in Cannabis Regulations Open the Door for Continued Global Growth
The movement for cannabis legalization began back in the 1990s when California became the first U.S. state to legalize medical cannabis. Subsequently, several other states began . . .
Posted on 7/1/19
Pfizer Completes Acquisition of Therachon
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the . . .
Posted on 7/1/19
Palatin Technologies Provides Mid-Calendar Year Corporate Update
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial . . .
Posted on 7/1/19
Bristol-Myers Squibb Completes Divestment of UPSA
Bristol-Myers Squibb Company (NYSE:BMY) announced today that effective July 1, 2019 it has completed its previously announced divestment of its consumer health business, UPSA
Posted on 7/1/19
Merck: Don't Miss It
SummaryKeytruda continues to dominate its field, applications in more critical situations could be possible.Top selling products continue to deliver strong results, patent life on average gives . . .
Posted on 7/1/19
Pfizer's About to Enter a Sales Slump -- Here's Why You Should Like the Stock Anyway
Some investing decisions seem like no-brainers. If you know that a company's sales growth is about to evaporate, staying away from the stock makes a lot . . .
Posted on 7/1/19
3 Top Biotech Stocks to Add to Your Watchlist
Biotech investing isn't for the faint of heart. The odds that any particular candidate treatment will be a success are low, and commercializing a drug is . . .
Posted on 6/30/19
Akari Therapeutics Announces $4.5 Million Registered Direct Offering
NEW YORK and LONDON, June 28, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune . . .
Posted on 6/30/19
Athenex Announces Strategic Global Initiatives to Expand Clinical Operations
BUFFALO, N.Y., June 28, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies . . .
Posted on 6/27/19
Konica Minolta Healthcare Partners With DiA Imaging Analysis
DiA Imaging Analysis, a leading provider of artificial intelligence (AI) powered ultrasound analysis solutions, announced today that it has partnered with Konica Minolta Healthcare Americas Inc., . . .
Posted on 6/27/19
Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb
The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug . . .
Posted on 6/27/19
Hoth Therapeutics Enters into Sponsored Research Agreement with the George Washington University
Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well . . .
Posted on 6/27/19
MetLife Joins Catalyst CEO Champions for Change
NEW YORK--(BUSINESS WIRE)--MetLife announced today that it has joined the Catalyst CEO Champions For Change, a transformational diversity and inclusion project launched by Catalyst, a leading . . .

